Slide 1: HFSA Annual Scientific Meeting
HFSA ANNUAL SCIENTIFIC MEETING Where Heart Failure Teams Gather September 26-29 | Minneapolis, Minnesota yp
Slide 2: Authors, presenter and affiliation
Authors: Ahmad Masri, Daniel P. Judge, Frederick L. Ruberg, Justin L. Grodin, Laura Obici, Mathew S. Maurer, Marianna Fontana, Steen Hvitfeldt Poulsen, Peter van der Meer, Richard K. Cheng, Amrut Ambardekar, Kuangnan Xiong, Suresh Siddhanti, Jean-François Tamby, Jonathan C. Fox, Kevin M. Alexander a
Slide 3: Disclosures
Ahmad Masri has acted as a researcher for Attralus, Cytokinetics, Ionis Pharmaceuticals, and Pfizer; and as a consultant, advisor, or speaker for Akros Pharma, Alexion Pharmaceuticals, Alnylam Pharmaceuticals, AstraZeneca, Attralus, BioMarin Pharmaceutical, BridgeBio Pharma Inc., Bristol Myers Squib
Slide 4: Background and learning objective
ATTR-CM is a progressive cardiomyopathy caused by destabilization of the TTR tetramer, resulting in a substantial burden of recurrent CV events1,2 Acoramidis is an oral TTR stabilizer that achieves near-complete (≥ 90%) TTR stabilization, and is approved in the USA, Europe, Japan, and the UK for the
Slide 5: ATTRibute-CM and OLE study design
ATTRibute-CM (30 Months) OLE Completed Month 30 and invited to enroll in the OLE (n = 438) 89% met eligibility criteria and elected to enroll in the OLEa (n = 389) 800 mg acoramidis HCl BID 800 mg acoramidis HCl BID Continuous Analysis Through Month 30b 2 Male: 89.6% mITT, n = 409 mITT, n = 258 acor
Slide 6: Baseline demographic and characteristics
Baseline Acoramidis Placebo Overall Demographic/Characteristic (n = 409) (n = 202) (N = 611) Age, years, mean (SD) 77.3 (6.5) 77.0 (6.7) 77.2 (6.6) Sex, male, n (%) 374 (91.4) 181 (89.6) 555 (90.8) Wild-type ATTR-CM, n (%)a 370 (90.5) 182 (90.1) 552 (90.3) 2273 2274 2273 NT-proBNP, pg/mL, median (IQ
Slide 7: Participants with CVM or recurrent CVH
Acoramidis Placebo (n = 409) (n = 202) Participants with CVM 136 (33.3) 98 (48.5) or recurrent CVH, n (%) Hazard ratio 0.51 (95% CI)b (0.43, 0.62) p value < 0.0001 Data are for the mITT population in the ATTRibute-CM study, defined as all the participants who had undergone randomization, rece
Slide 8: Fewer cumulative events with acoramidis through Month 30
Numerically fewer cumulative events were observed with acoramidis from Month 1 through Month 30 vs placebo Acoramidis Placebo (n = 409) (n = 202) Difference in mean 53 per 100 participants cumulative events at (29, 79) Month 30 (95% CI)a Data are for the mITT population in the ATTRibute-CM study,
Slide 9: Data are for the mITT population in the ATTRibute-CM study, defined as all the
Data are for the mITT population in the ATTRibute-CM study, defined as all the participants who had undergone randomization, received at least one dose of acoramidis or placebo, and had at least one efficacy evaluation after baseline; participants with eGFR < 30 mL/min/1.73 m2 were excluded CV, card
Slide 10: Participants with CVM, hazard ratio
Acoramidis Placebo (n = 409)a (n = 202)a Participants with CVM, 68 (16.6) 58 (28.7) n (%) Hazard ratio 0.55 (95% CI)b (0.39, 0.79) p value 0.0011 Data are for the mITT population in the ATTRibute-CM study and its OLE, defined as all the participants who had undergone randomization, received at
Slide 11: Recurrent CVH with acoramidis vs placebo
Numerically fewer cumulative events were observed with acoramidis from Month 1 through Month 30 vs placebo Acoramidis Placebo (n = 409) (n = 202) Participants with 109 (26.7) 86 (42.6) recurrent CVH, n (%) Relative risk ratio 0.50 (95% CI)a (0.35, 0.69) p value < 0.0001 Data are for the mITT popul
Slide 12: Difference in mean cumulative events of CVM or recurrent CVH
CVM or Recurrent CVH Difference in Mean Cumulative Events of CVM or Recurrent CVH Numerical difference by Month 1 • Almost 25% of cumulative CV events occurred within the first 6 months Data are for the mITT population in the ATTRibute-CM study, defined as all the participants who had undergone rand
Slide 13: Acoramidis significantly reduced risk of cumulative events
Acoramidis treatment over 30 months significantly reduced the risk of cumulative events of CVM or recurrent CVHa by 49% (hazard ratio [95% CI]: 0.51 [0.43, 0.62]) vs placebo Numerically fewer cumulative events were observed with acoramidis vs placebo as early as Month 1 The difference in mean cumula
Slide 14: Acknowledgments
The authors would like to thank the patients who participated in the ATTRibute-CM trial, their families, and their caregivers The authors would also like to thank the ATTRibute-CM investigators and study center staff Under the guidance of the authors, medical writing assistance was provided by Oxfor
Slide 15: Scan QR code to access the article
Scan the QR code to access the article, a PLS of the article, and a PDF version of this presentation Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM: Exploratory Analysis from ATTRibute-CM Ahmad Masri, Daniel P. Judge, Frederick L. Ruberg, Julian D. Gillmore, Just